This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.
ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors
Julia Hofmann
Head of Corporate Communications
Phone: +49 89 329 8986 1500